drugset / Trial / NCT02839915

Leucovorin for the Treatment of Language Impairment in Children With Autism Spectrum Disorder

NCT02839915 ↗

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine the effectiveness of folinic acid in the treatment of language problems in children with autism spectrum disorder. Folinic acid, also known as leucovorin, is approved by the U.S. Food and Drug Administration (FDA) to decrease side effects during cancer chemotherapy. Folinic acid may be helpful in treating language problems in children with autism spectrum disorder, but this is not known. Therefore, folinic acid is an investigational new drug for this study. Investigators will enroll a total of 134 participants across all three centers, over a 5 year period and participation will last between 12 and 24 weeks.

Timeline

Start
2020-08-13
Primary completion
2024-04-15
Completion
2026-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Leucovorin Small molecule 1 mg/kg Oral